27
Comments
• Chlorthalidone is preferred on the basis of prolonged half-life and proven trial
reduction of CVD.
• Monitor for hyponatremia and hypokalemia, uric acid and calcium levels.
• Use with caution in patients with history of acute gout unless patient is on
uric acid–lowering therapy.
• Do not use in combination with ARBs or direct renin inhibitor.
• There is an increased risk of hyperkalemia, especially in patients with CKD or in
those on K
+
supplements or K
+
-sparing drugs.
• There is a risk of acute renal failure in patients with severe bilateral renal artery
stenosis.
• Do not use if patient has history of angioedema with ACE inhibitors.
• Avoid in pregnancy.
• Do not use in combination with ACE inhibitors or direct renin inhibitor.
• There is an increased risk of hyperkalemia in CKD or in those on K
+
supplements or
K
+
-sparing drugs.
• There is a risk of acute renal failure in patients with severe bilateral renal artery
stenosis.
• Do not use if patient has history of angioedema with ARBs. Patients with a history of
angioedema
• with an ACE inhibitor can receive an ARB beginning 6 weeks after ACE inhibitor is
discontinued.
• Avoid in pregnancy.